Buy fine quality research chemicals from Shanghai Chemical International Trade Co., Ltd



Deschloroetizolam – A short-acting psychoactive drug

Deschloroetizolam is a new research chemical. The preparation of Deschloroetizolam was described in a patent in 1988. Deschloroetizolam is a benzodiazepine. It is an analog of the drug classified Etizolam, but a chlorine atom is less present in the benzene ring. Deschloroetizolam is sold for legal purposes only. The use of Deschloroetizolam on humans and animals is prohibited.

The pharmacological mode of action of the benzodiazepines is based on the molecular binding at the benzodiazepine binding site of the gamma-aminobutyric acid receptor (GABA receptor) in the central nervous system. As a result of the binding, the inhibitory effect triggered by GABA is amplified. As a result, the nonspecific slowing of the activity of the nerve tracts leads to a soothing, soporific and anxiety-suppressing effect of the benzodiazepines. The effect of the benzodiazepines is almost complete in the central nervous system.

The efficacy of Deschloroetizolam is described as similar to Etizolam on internet foraging, but it is longer with duration of over 8 hours. In this respect, it is comparable to the medium-duration benzodiazepines such as Alprazolam and Oxazepam. In general, the market for designer drugs and also the designer benzodiazepines is that there are no controlled marketing channels or quality requirements for these products, even if they are marketed as tablets with strength. The consumer reports on the consumption doses are therefore not reliable with respect to the purity or strength of the substances.

View Also

  • Pyrazolam
  • Diazepine
  • Clonazepam (this does not have a triazole ring)
  • Meclonazepam
  • Clonitrazolam
  • Estazolam (licenced)
  • Triazolam
  • Nitrazolam
  • Nifoxipam

Common adverse side effects of benzodiazepines include muscle weakness, coordination disorders, nausea, memory impairment, and somnolence. The inhibitory effect on the central nervous system is caused by the simultaneous consumption of alcohol or psychoactive drugs, such as sleeping pills, tranquilizers, and antipsychotic drugs.

The use of benzodiazepines can easily lead to the development of tolerance and the long-term application can lead to a physical and psychological dependence on these substances. The risk of addiction increases with the dosage and the duration of consumption. The risk is increased by simultaneous use of several benzodiazepines.

Risks to the health and social risks of Deschloroetizolam are higher than the corresponding risks of other benzodiazepines, For example, in the impairments caused by fatigue and memory impairment during professional activity and transport. The development of tolerance and dependency and the resulting urge to consume the substance can lead in the worst case to the criminality and neglect of other obligations.

Deschloroetizolam and other designer benzodiazepines have been included in the general abuse of benzodiazepines, also used for medical purposes. The duration of Deschloroetizolam is comparable to the mean duration of benzodiazepines classified as anesthetics. Benzodiazepines with a long duration of action can also cause motor and cognitive impairments due to their accumulation in the organism for a long time after the last dose.

There is no certainty about the quality of substances that are similar to medical products, but their consumers are found outside the production and distribution channels of legal medicines. Therefore, there is no certainty about the content or purity of such substances and the products that they contain so that their use is always more dangerous than that of medications of recognized quality.